Spero Therapeutics, Inc. Banner Image

Spero Therapeutics, Inc. has reached its limit for free report views

Work for Spero Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Spero Therapeutics, Inc.

  • Ticker SPRO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Spero Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases. Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for useMore in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. Spero is also advancing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.
Spero Therapeutics, Inc.

Most Recent Annual Report

Spero Therapeutics, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Spero Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports